

**From:** [Broadcast Notifications](#)  
**To:** [Broadcast Notifications](#)  
**Subject:** Referral and Availability of Emergency Use Authorization SARS-CoV-2 Monoclonal Antibody Therapies  
**Date:** Tuesday, April 6, 2021 2:43:52 PM

---



---

**TO:** All Faculty, Staff, Trainees, and Students

**FROM:** **Judith A. Aberg, MD**  
Chief of Infectious Diseases  
Mount Sinai Health System  
Dean of System Operations for Clinical Sciences  
Icahn School of Medicine at Mount Sinai

**Brendan G. Carr, MD, MS**  
Professor and Chair  
Department of Emergency Medicine  
Mount Sinai Health System

---

**April 6, 2021**

**Referral and Availability of Emergency Use Authorization SARS-CoV-2  
Monoclonal Antibody Therapies**

The Mount Sinai Health System has combination monoclonal therapies available that, according to research, may decrease the need for hospitalization in some patients.

Data from randomized controlled trials suggest that [SARS-CoV-2 specific monoclonal antibody therapies](#) can decrease the amount of virus in one's system and decrease the need for hospitalization in some patients. These therapies have been made available under an emergency use authorization (EUA) for patients with laboratory-confirmed COVID-19, mild to moderate symptoms, and specified risk factors for progression to severe disease.

Two combination monoclonal therapies are available:  
[bamlanivimab/etesevimab](#) and [casirivimab/imdevimab](#).

**Ambulatory patients with all of the following can be referred for therapy:**

- A documented diagnostic SARS-CoV-2 test (PCR/ NAA or antigen) within five days of referral. Due to occasional false-positive antigen results, corroborating clinical and epidemiologic information may be requested prior to referral for infusion.
- Symptoms attributable to COVID-19 with onset within five days of referral.
- At least one risk factor for progression to severe disease as outlined in the health care provider fact sheets for [bamlanivimab/etesevimab](#) and [casirivimab/imdevimab](#).

Infusions are available across the Health System, including in most of our Emergency Departments. COVID-19 vaccination will be deferred for 90 days from the receipt of SARS-CoV-2 specific monoclonal therapies. Previous receipt of COVID-19 vaccine does not exclude a patient from being referred.

Referrals can be made by emailing [covidtherapeuticreferrals@mountsinai.org](mailto:covidtherapeuticreferrals@mountsinai.org) or calling (212) 824-8390. Infusions are available at Mount Sinai South Nassau by calling (516) 632-4998. Please include the patient's full name, date of birth, and contact information as well as the referring provider's contact information if available.

